IJACT, Volume 3, Issue 2, 2025 ISSN: 2995-5378
http://medicaljournals.eu/index.php/IJACT

INTERNATIONAL JOURNAL OF ALTERNATIVE AND CONTEMPORARY THERAPY

Indications for the Use of Antidepressants and Prospects for Reducing Side Effects Associated with Their Use

Sokhib Rashidov Zamon o‘g‘li, Azizbek Sharibjonov Sharibjon o‘g‘li
Tashkent medical academy

Abstract: This activity reviews the indications, contraindications, action, adverse events, and other important aspects of antidepressant therapy in the clinical setting as it relates to the crucial information required by members of an interprofessional team managing the care of patients receiving antidepressant medications for conditions that respond to this medication class. Although antidepressants may be the drug of choice for depression, they also have FDA approval as treatments for other medical disorders, such as obsessive-compulsive disorder, social phobia, panic disorder, generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD). The findings indicate that there is no discernible difference in the reduction of depressive symptoms in persons with non-severe depression between pharmaceutical and exercise therapies. Exercise as an adjuvant or alternative treatment for persons with non-severe depression is supported by these data. Depression can be effectively treated with exercise, and strength training, yoga, and jogging or walking are more beneficial than other forms of exercise, especially when done vigorously. Comparing yoga and strength training to other treatments, they were well tolerated. People with varying baseline levels of depression and those without comorbidities seemed to benefit equally from exercise. In order to reduce expectancy effects, future research could try to blind staff and participants. These types of exercise could be viewed as essential treatments for depression, in addition to psychotherapy and antidepressants.

Keywords: Depression, pharmacological treatments, non-severe symptoms, obsessive-compulsive disorder, contraindications, action, adverse events.

Introduction. An estimated more 300 million individuals worldwide suffer from depression, which is one of the main causes of disability. Depression has a detrimental impact on role functioning and quality of life, and its cost in lost productivity alone is estimated to be over more US$900 billion. Up to 19% of people may experience depression in their lives, and it is strongly linked to the development of various mental and physical illnesses. Nowadays, one of the first-line therapies for depression is the use of second-generation antidepressant drugs. The data supporting their efficacy is still debatable, though, as the long-term balance between benefit and harm is not well established and the immediate and short-term advantages may be minimal. The efficiency of antidepressants and the severity of depressive symptoms are directly correlated, according to individual-level meta-analyses [1,2,3]. The benefits of antidepressants in non-severe depression have thus been argued to be minimal, which is concerning because the majority of patients with depression report symptoms below the threshold for severe depression. Additionally, the applicability of antidepressants in some real-life settings is limited by high costs, fear of addiction, and potential adverse effects. Patients with non-severe symptoms may also be reluctant to use antidepressants due to low perceived need or effectiveness of the medication and/or social stigmatization. While there is evidence that antidepressants have some beneficial effects on milder forms of depression when compared with a placebo, concerns regarding the risk-benefit ratio and the availability of alternative treatments raise questions regarding the appropriateness of pharmacological treatments for non-severe depression [4,5,6,7]. Lifestyle interventional strategies that include diet, sleep, and physical activity have recently been recognized as protective treatments for depression. In particular, several treatment guidelines support the use of exercise as an alternative treatment for non-severe depression, while the Diagnostic and Statistical Manual of Mental Disorders'

clinical practice guidelines support exercise therapy only when antidepressants or psychotherapy treatments are ineffective or unacceptable. Additionally, the DSM-5 guidelines state that there is insufficient evidence to recommend exercise as an official treatment, which contradicts the European Psychiatric Association's report that there is sufficient data supporting exercise for the management of mild-to-moderate depression. These contradictory statements make it impossible to draw firm conclusions about the role of exercise [8,9,10]. To determine if exercise is an effective non-pharmacological therapeutic strategy for managing non-severe depression and to inform existing worldwide treatment guidelines about the protective role of exercise in depression, it is imperative to compare the effects of exercise and antidepressants. Therefore, in order to ascertain the relative efficacy of exercise and pharmaceuticals on depressive symptoms in individuals with non-severe depression, we carried out a systematic review and network meta-analysis. In order to investigate the possible synergistic influence of exercise and antidepressants, we also compared the effects of combination treatment to each treatment alone. As a gauge of treatment acceptance, we also planned to compare participant dropout rates across therapies [11,12,13,14,15].

The inclusion criteria, which included research synthesis including systematic reviews, meta-analyses, umbrella reviews, individual patient meta-analyses, and large dataset analysis, were created to find the best available evidence in each study area. studies in which participants have depressive disorders or in which mood symptoms are recorded as a result of an experiment.investigations of experimental protocols using a control or sham condition. studies that have been fully published in peer-reviewed journals. The most recent five systematic reviews or major analyses are included where there are more than five.

NMDA Inhibitors. Esketamine: When used in conjunction with an oral antidepressant, intranasal esketamine has FDA approval for treating people with treatment-resistant depression. It is also recommended for people with serious depressive illness who have suicidal thoughts or actions. For major depressive disorder, the FDA has approved a fixed medication combination (FDC) of bupropion and dextromethorphan. Under priority review, the FDA designated dextromethorphan/bupropion as a breakthrough treatment. According to a meta-analysis of the comparative effectiveness of antidepressant findings, escitalopram and sertraline are more effective than other medications and cause less adverse drug effects. For unipolar major depression, sertraline or escitalopram is therefore the first medication of choice [16-20]. The FDA has approved antidepressants as treatments for a number of medical conditions, but they are the preferred medication for depression. Generalized anxiety disorder (GAD), panic disorder, social phobia, obsessive-compulsive disorder, and post-traumatic stress disorder (PTSD) can all be effectively treated with antidepressants. There are other off-label, non-FDA-approved uses for antidepressants. Tricyclic antidepressants, for instance, are recommended to treat migraine, pain, and sleeplessness. Off-label treatment for insomnia involves the use of the serotonin modulator trazodone [1-26].

Action Mechanism. In order to alter mood and behavior, the antidepressants all target specific neurotransmitters in slightly different ways. It is thought that serotonin, norepinephrine, or both are increased in the synapse by all currently approved antidepressants. Although antidepressant medications target reuptake by the nerve terminals, there are many ways to enhance these neurotransmitters. Neuronal uptake is the main mechanism by which neurotransmission via 5HT is stopped; SERT mediates the reuptake of 5HT into presynaptic terminals. SSRIs increase and prolong serotonergic neurotransmission while blocking reuptake. Continuous SSRI delivery results in long-lasting increases in nuclear transcription factor phosphorylation and cyclic AMP signaling, as well as enhanced neurogenesis and trophic factor expression, including BDNF. The first-line treatment for depression at the moment is SSRIs. By preventing serotonin and norepinephrine from being reabsorbed in the synapse, serotonin and norepinephrine reuptake inhibitors (SNRIs) increase the activation of postsynaptic receptors. The way that SNRIs bind to the serotonin and norepinephrine transporter varies. Milnacipran and levomilnacipran, in contrast to other selective serotonin-norepinephrine reuptake inhibitors such as duloxetine, venlafaxine, and desvenlafaxine, have higherselectivity for inhibiting norepinephrine reuptake than serotonin reuptake [27-33].

Negative consequences. Sexual dysfunction, sleepiness, weight gain, insomnia, anxiety, headache, dizziness, blurred vision, nausea, rash, and tremor are among the most common antidepressant adverse effects. While using antidepressants, patients may also experience malaise and asthenia. In patients using antidepressants, clinicians may observe signs of hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and hyperprolactinemia [11-15].

Contraindications. The use of antidepressants may not be appropriate in a number of situations. Both inside and between classes, these situations differ. Patients with known hypersensitivities or those on other psychiatric medicines should utilize antidepressants with caution. Because serotonin syndrome can cause severe neuromuscular and autonomic symptoms, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors, for instance, should not be taken with other SSRIs, monoamine oxidase inhibitors, tricyclic antidepressants, and other psychotropics.Another excellent illustration of relative contraindications in antidepressant therapy is tricyclic antidepressants. When giving tricyclic antidepressants to patients who have cardiovascular illness, clinicians should use caution. It has been demonstrated that tricyclic antidepressants can result in orthostatic hypotension. Tricyclic antidepressants can also cause heart block in people who already have bundle-branch disease [1,5,6,7,11]. Seizures are indicated as a serious contraindication for the atypical antidepressant buproprion. Patients with an active seizure diagnosis or a history of seizure activity are contraindicated. Patients taking monoamine oxidase inhibitors or medications that can lower the seizure threshold should not take bupropion, as they should not take other antidepressants. Nefazodone therapy is contraindicated in patients with liver damage from prior treatment. According to the product label, esketamine should not be used in cases of arteriovenous malformations or aneurysmal vascular disease (thoracic and abdominal aorta, intracranial, and peripheral arterial arteries). Patients with seizure disorders, bulimia/anorexia nervosa, concurrent use of MAO inhibitors, or within 14 days of ceasing dextromethorphan/bupropion treatment are contraindicated for this medication [14-21].

Monitoring of Therapeutic Drugs. Keeping an eye on their patients' antidepressant levels may be helpful to clinicians. This therapeutic drug monitoring approach is predicated on antidepressant serum or plasma concentrations, which scientists consider to be a more accurate indicator than dosage. When antidepressants have a well-established therapeutic range, therapeutic drug monitoring is advantageous. However, patients who have a history of noncompliance, unpleasant effects, or are refractory to treatment may also benefit from it. Because therapeutic medication monitoring is costly, physicians must balance the study's advantages against its costs [22-28].

Improving the Results of Healthcare Teams. Many patients do not obtain proper treatment, even though antidepressants are helpful in treating depression and its associated indications. Clinical professionals must use an interprofessional team-centered approach to effectively diagnose and treat depression, educate patients, use evidence-based medication, closely monitor patients for compliance, identify side effects, and assess treatment efficacy. Research indicates that a number of factors influence how well patients take their antidepressants. In general, adherence was predicted by worries about adverse drug effects. Comorbidities among patients may also influence their adherence to antidepressant prescriptions. Conditions that affect a person's cognitive status in particular may cause non-compliance. Reduced adherence was predicted by factors such as alcohol or drug misuse, cardiovascular illness, metabolic diseases, youth, low-income housing, and the use of antidepressant medications from older generations, especially in the acute phase [5-11]. The treatment of depression and the prescription of antidepressant drugs depend heavily on recognizing and resolving these issues. When treating depression, the collaborative care method is supported by a number of randomized controlled trials. The patient, prescribing physician, psychiatric consultant, and depression care manager are suggested to be included in the program. The depression care manager will oversee the antidepressant regimen, conduct education, and arrange for referrals as needed. The psychiatric consultant will be in charge of enhancing treatment plans for patients who aren't living up to expectations. It is possible for patients to be on many antidepressant medications concurrently. Therefore, for the emergency physicians and triage nurses, it is crucial to identify all the medicines involved in poisoning [18-22]. Nursing personnel and pharmacists are additional parts of the

healthcare team who must help with antidepressant care. Specialized nurses in psychiatry are better suited to identify treatment failure, provide drug advice, track side effects, and evaluate patient compliance. In addition to doing medication reconciliation for drug interactions, pharmacists are able to confirm agent selection and dosage. The prescriber must be easily accessible to nurses and pharmacists in case of concern. When a patient overdoses on antidepressants, emergency room doctors should stabilize them quickly to ensure proper breathing, circulation, and airway. ICU care must be provided under the direction of a critical care physician for cardiac arrhythmias, serotonin syndrome, and seizures. When poisoning is serious, medical toxicologists should be consulted. For intentional overdose, a psychiatrist must be consulted. As previously mentioned, the patient undergoing antidepressant therapy is cared for by a variety of healthcare professionals, including nurses, pharmacists, specialists, and doctors. When all members of the interprofessional team work together, they may avoid negative reactions and maximize effectiveness, which will result in the best possible outcomes for patients [23-31].

Materials and Methods

The methodology employed in this study involved a systematic review and network meta-analysis to assess the indications for antidepressant use and the potential strategies for minimizing their side effects. The research included a comprehensive analysis of peer-reviewed studies, systematic reviews, and meta-analyses published within the last five years, ensuring the inclusion of the most recent and relevant findings. Data was extracted from clinical trials evaluating the efficacy and safety of various antidepressant classes, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and atypical antidepressants. The study also explored alternative treatment strategies, such as exercise and cognitive behavioral therapy, assessing their comparative effectiveness in treating non-severe depression. The review incorporated both direct and indirect comparisons between pharmacological and non-pharmacological interventions, considering dropout rates and adherence levels as indicators of treatment acceptability. Special emphasis was placed on the mechanisms of antidepressant action, neurotransmitter modulation, and the role of NMDA inhibitors such as esketamine. The analysis further investigated the adverse effects of antidepressants, including weight gain, sexual dysfunction, and withdrawal symptoms, identifying risk factors associated with increased side effects. Contraindications, including cardiovascular risks and interactions with other medications, were critically examined to provide a comprehensive risk-benefit assessment. The findings were synthesized to inform clinical guidelines on optimizing antidepressant therapy while considering patient preferences, treatment adherence, and the potential for personalized medicine. The study contributes to the ongoing discussion on improving depression management by integrating pharmacological and lifestyle-based interventions to enhance patient outcomes.

Results and Discussion. The results of this study, which is the first network meta-analysis to compare the effects of exercise, antidepressants, and combined treatments on depressive symptoms in adults with non-severe depression, showed that all treatments had similar beneficial effects on depressive symptoms when compared to the controls, but no treatment was superior to the others. Acceptability assessments revealed that antidepressant treatments caused fewer intervention drop-outs than exercise. These findings are consistent with the recommendations made by European, Canadian, Australian, and UK treatment guidelines that support the use of exercise as an alternative treatment for non-severe depression. These guidelines recommend moderately intense 30- to 60-minute sessions of exercise to be conducted two to three times a week for 9 to 12 weeks, and that are led by qualified professionals in groups [1,2,3,11,14]. The DSM-5 recommendations, on the other hand, do not recommend exercise therapy as a first-line treatment, only for those who do not respond to antidepressant or psychotherapy treatment.Crucially, they provide therapy recommendations based on multiple reviews that satisfy quality standards rather than classifying depression according to the intensity of symptoms. With the exception of one, every review that was included in their evaluation was only concerned with pharmacological or psychotherapy therapies. The authors solely examined direct evidence when comparing pharmaceutical and non-pharmacological therapy. As a result, two exercise studies were

included, and it was determined that there was not enough data to support the use of exercise as a treatment for depression. Exercise and antidepressants did not differ in their ability to treat depression, according to the direct and indirect data we collected for this study [14,15,16,17,18]. Due to the small number of studies we included in our analyses, combination treatment did not show more positive benefits on depressive symptoms than either treatment alone. It's still not quite apparent how exercise and medication work together to treat depression. There is currently conflicting evidence about the combined efficacy of the two therapies compared to pharmaceutical treatment alone, despite some research attempting to explain the potential synergism between them. Although our research does not support the idea that exercise and antidepressants work in concert, given the many health advantages of physical activity, combining exercise with pharmacotherapy may help patients recover more quickly and mitigate the negative side effects that are frequently linked to antidepressant use [11-17]. Several antidepressant studies in mild-to-moderate depression were excluded as a result, and overall, the proportion of studies evaluating treatment effectiveness in mild-to-moderate depression and those focusing on severe depression is out of balance. This imbalance has been attributed in part to the inclusion criteria used for FDA-funded trials, which impose higher cut-off scores at baseline to increase the sensitivity of the antidepressant versus placebo comparison. We hope that the current study will help to highlight the clinical importance of non-severe depression and that more clinical trials on non-severe depression can be carried out in the future [31-37].

Conclusions. According to the findings, there is no discernible difference between pharmaceutical and exercise therapies in terms of lowering depressed symptoms in people with mild to moderate depression. These results provide credence to the use of exercise as a supplement or alternative therapy for persons with mild to moderate depression.

When a patient overdoses on antidepressants, emergency room doctors should stabilize them quickly to ensure proper breathing, circulation, and airway. ICU care must be provided under the direction of a critical care physician for cardiac arrhythmias, serotonin syndrome, and seizures. When poisoning is serious, medical toxicologists should be consulted. For intentional overdose, a psychiatrist must be consulted. As previously mentioned, the patient undergoing antidepressant therapy is cared for by a variety of healthcare professionals, including nurses, pharmacists, specialists, and doctors. When all members of the interprofessional team work together, they may avoid negative reactions and maximize effectiveness, which will result in the best possible outcomes for patients.

Further trials directly comparing the individual and synergistic action of exercise and antidepressants are warranted to corroborate the findings of this study. The meta-analytical evidence collected through direct and indirect comparisons found no differences in treatment effectiveness between exercise, antidepressants, and their combination. These findings support the use of exercise interventions as an alternative treatment option for non-severe depression. Results were corroborated through rigorous sensitivity analyses that accounted for the quality of studies as well as types of participants and interventions.

References.

1. Eveleigh R, Speckens A, van Weel C, Oude Voshaar R, Lucassen P. Patients' attitudes to discontinuing not-indicated long-term antidepressant use: barriers and facilitators. Therapeutic Advances in. Psychopharmacology. 2019;9:204512531987234.
2. Maund E, Dewar-Haggart R, Williams S, Bowers H, Geraghty AWA, Leydon G, et al. Barriers and facilitators to discontinuing antidepressant use: A systematic review and thematic synthesis. J Affect Disord. 2019;245:38–62.
3. Sheffler ZM, Patel P, Abdijadid S. Antidepressants. [Updated 2023 May 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538182/

4. Weinstein JJ, Rogers BP, Taylor WD, Boyd BD, Cowan RL, Shelton KM, et al. Effects of acute tryptophan depletion on raphé functional connectivity in depression. Psychiatry Res. 2015;234:164–71.

5. Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4-oxadiazole-2-thion (D-361). *International Journal of Medical Sciences And Clinical Research*, *2*(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01

6. Zimmermann M, Papa A. Causal explanations of depression and treatment credibility in adults with untreated depression: Examining attribution theory. Psychol Psychother. 2020;93:537–54.

7. Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. *Texas Journal of Medical Science*, *13*, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434

8. Moncrieff, J., Cooper, R.E., Stockmann, T. *et al.* The serotonin theory of depression: a systematic umbrella review of the evidence. *Mol Psychiatry* **28**, 3243–3256 (2023). https://doi.org/10.1038/s41380-022-01661-0

9. Rakhimboev S.D., Sanoev Z.I., Rashidov S.Z., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Screening Study of the Anxiolytic Activity of New Triazole Compounds. Texas Journal of Medical Science, 13, 1–4. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2450

10. Noetel M, Sanders T, Gallardo-GÃ³mez D, Taylor P, del Pozo Cruz B, van den Hoek D et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials BMJ 2024; 384 :e075847 doi:10.1136/bmj-2023-075847

11. S.D. Rakhimboev, Z.I. Sanoev, T.T. Khamroev, S.Z. Rashidov, I.T. Abdinazarov, D.S. Ismailova, & B.J. Elmuradov. (2022). Screening study of neurotropic properties of new triazole derivative. Oriental Journal of Medicine and Pharmacology, 2(04), 12–20. https://doi.org/10.37547/supsci-ojmp-02-04-02

12. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008 Jun;69(6):946-58. doi: 10.4088/jcp.v69n0610.

13. Саноев З.И., Ҳамроев Т.Т., Абдиназаров И.Т., Садиков А.З., Рахимбоев С.Д., Рашидов С.З. N–дезацетиллаппаконитин (N- ДАЛ) нинг тутқаноққа қарши фаоллигини ўрганиш. Oriental journal of medicine and pharmacology. Pages: ISSN: 2181-2799 Year 2022 29-37 DOI: https://doi.org/10.37547/supsci-ojmp-02-02-04.

14. Recchia F, Leung CK, Chin EC, et alComparative effectiveness of exercise, antidepressants and their combination in treating non-severe depression: a systematic review and network meta-analysis of randomised controlled trialsBritish Journal of Sports Medicine 2022;56:1375-1380.

15. Sanoev Z.I., Khamroev T.T., Abdinazarov I.T., Rakhimboev S.D., Rashidov S.Z., Evaluation of Anticonvulsant Activity of Allapinine and N-Deacetylappaconitine in Experimental Animals. Journal Healthcare Treatment Development(JHTD). Volume 01 issue 02 October - November 2021. http://journal.hmjournals.com/index.php/JHTD/article/view/1378

16. Kutkat, O., Moatasim, Y., Al-Karmalawy, A.A. et al. Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies. Sci Rep 12, 12920 (2022). https://doi.org/10.1038/s41598-022-17082-6

17. Т.Т.Ҳамроев, Н.М.Маматқулова, П.А.Нурмахмадова, С.З.Рашидов, И.Т.Абдиназаров, С.Д.Раҳимбоев, Н.Қ.Хидирова, У.М.Якубов. (2022). Adonis turkestanica ўсимлигининг

экстракция жараёнида ҳосил бўлган қолдиқ моддаларнинг ўткир заҳарлилиги ва биологик фаоллигини скрининг тадқиқотларда ўрганиш. Eurasian journal of academic research, 2(12), 447–454. https://doi.org/10.5281/zenodo.7332870

18. Alsharji, K. E. Anxiety and depression during the COVID-19 pandemic in Kuwait: the importance of physical activity. Middle East Curr. Psychiatry 27, 60 (2020).
19. da Rosa, T. F. et al. Repositioning or redirection of antidepressant drugs in the treatment of bacterial and fungal infections. Am. J. Ther. 27, e528–e532 (2020).
20. Т.Т. Ҳамроев, Н.М. Маматқулова, З.И. Саноев, С.З. Рашидов, И.Т. Абдиназаров, П.А. Нурмахмадова, Н.Қ. Хидирова, У.М. Якубов. (2022). Adonis turkestanica ўсимлигининг экстракция жараёнида ҳосил бўлган қолдиқ моддаларнинг анксиолитик фаоллигини скрининг тадқиқотларда ўрганиш. Eurasian journal of medical and natural sciences, 2(12), 146–152. https://doi.org/10.5281/zenodo.7332882
21. Papakostas GI, Nutt DJ, et al. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006;60(12):1350–5. doi: 10.1016/j.biopsych.2006.06.015.
22. R. S. Z. ugli, T. A. A. ugli, B. Y. I. ugli, S. K. K. qizi, & ugli , M. I. Z. (2024). Features of Anti-Inflammatory Drugs and the Relevance of Creating New Anti-Inflammatory Drugs. American Journal of Bioscience and Clinical Integrity, 1(11), 130–135. Retrieved from https://biojournals.us/index.php/AJBCI/article/view/320
23. Zarate CA, Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry. 2006;59(11):1006–20. doi: 10.1016/j.biopsych.2005.10.021.
24. Albert PR, Benkelfat C, Descarries L. The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philos Trans R Soc Lond B Biol Sci. 2012;367:2378–81.
25. Zamon ugli, S. R., Yorqinzhon ugli, N. Z., Abdurazak ugli, K. M., Mirodil qizi, S. M., & Yusufzhon ugli, K. Y. (2024). Insufficient of Existing Drugs Used for Diabetes Ii Types and the Need to Improve Them. International Journal of Integrative and Modern Medicine, 2(11), 294–301. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/1219
26. Jakobsen JC, Gluud C, Kirsch I. Should antidepressants be used for major depressive disorder? BMJ Evidence-Based. Medicine. 2020;25:130–130.
27. Kennis M, Gerritsen L, van Dalen M, Williams A, Cuijpers P, Bockting C. Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2020;25:321–38.
28. Zamon ugli, S. R., Mekhriddin qizi, M. N., Zokirzhon qizi, K. S., Akmal qizi, D. R., & Sirozhiddin qizi, U. N. (2024). Important Aspects and Risk Factors for Hypertension in the Environment and Adverse Climate. International Journal of Integrative and Modern Medicine, 2(11), 302–307. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/1220
29. S. R. Z. ugli , , S. V. M qizi. Madiyorovna , K. A., ugli , E. A. I., & qizi, S. N. Q. (2024). In Patients with Gastroduodenal Peptic Ulcer Disease, an Analysis of the Immunological Properties of H.Pylori Infection. International Journal of Alternative and Contemporary Therapy, 2(11), 93–99. Retrieved from https://medicaljournals.eu/index.php/IJACT/article/view/1214
30. Yoon HS, Hattori K, Ogawa S, Sasayama D, Ota M, Teraishi T, et al. Relationships of cerebrospinal fluid monoamine metabolite levels with clinical variables in major depressive disorder. J Clin Psychiatry. 2017;78:e947–56.

31. S. R. Z. ugli, S. S. S. , ugli, , D. U. O. qizi, , G. N. B. qizi, & , S. A. T. qizi (2024). Modern Methods of Diagnosis of Osteoporosis, Advances in Treatment and Solutions to Existing Problems. International Journal of Alternative and Contemporary Therapy, 2(11), 100–106. Retrieved from https://medicaljournals.eu/index.php/IJACT/article/view/1215

32. Elmurod qizi, D. K., Samandarovna, S. A., Dilshod qizi, K. N., Quyli ugli, U. T., & Zamon ugli, S. R. (2024). Relevance and prospects of the search for drugs with anxiolytic activity. *International Journal of Cognitive Neuroscience and Psychology*, *2*(12), 27–33. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1320

33. Bobomurod qizi, E. L., Obidzhon qizi, I. O., Dilshodzhon qizi, D. A., Akbar qizi, G. U., & Zamon ugli, S. R. (2024). The role, application and necessity of research in medical practice of drugs with psychostimulating activity. *International Journal of Cognitive Neuroscience and Psychology*, *2*(12), 20–26. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1319

34. Kaufman J, DeLorenzo C, Choudhury S, Parsey RV. The 5-HT1A receptor in Major Depressive Disorder. Eur Neuropsychopharmacol. 2016;26:397–410.

35. Kambeitz JP, Howes OD. The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord. 2015;186:358–66.

36. Hogenelst K, Schoevers RA, Kema IP, Sweep FCGJ, aan het Rot M. Empathic accuracy and oxytocin after tryptophan depletion in adults at risk for depression. Psychopharmacology. 2016;233:111–20.

37. Fava GA. May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Therapeutic Adv Psychopharmacol. 2020;10:2045125320970325.